These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments. Koga T; Suda K; Fujino T; Ohara S; Hamada A; Nishino M; Chiba M; Shimoji M; Takemoto T; Arita T; Gmachl M; Hofmann MH; Soh J; Mitsudomi T J Thorac Oncol; 2021 Aug; 16(8):1321-1332. PubMed ID: 33971321 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of ULK1/2 and KRAS Ghazi PC; O'Toole KT; Srinivas Boggaram S; Scherzer MT; Silvis MR; Zhang Y; Bogdan M; Smith BD; Lozano G; Flynn DL; Snyder EL; Kinsey CG; McMahon M bioRxiv; 2024 Jun; ():. PubMed ID: 38370808 [TBL] [Abstract][Full Text] [Related]
12. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun. Bungaro M; Novello S; Passiglia F Curr Treat Options Oncol; 2022 Dec; 23(12):1699-1720. PubMed ID: 36394791 [TBL] [Abstract][Full Text] [Related]
13. AMG-510 and cisplatin combination increases antitumor effect in lung adenocarcinoma with mutation of KRAS G12C: a preclinical and translational research. Wu LL; Jiang WM; Liu ZY; Zhang YY; Qian JY; Liu Y; Huang YY; Li K; Li ZX; Ma GW; Xie D Discov Oncol; 2023 Jun; 14(1):91. PubMed ID: 37284902 [TBL] [Abstract][Full Text] [Related]
15. Multiple initiatives to conquer KRAS G12C inhibitor resistance from the perspective of clinical therapy. Zhang J; Zhang J; Leung EL; Yao XJ Expert Opin Investig Drugs; 2023 Feb; 32(2):101-106. PubMed ID: 36749819 [TBL] [Abstract][Full Text] [Related]
16. Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer. Adachi Y; Ito K; Hayashi Y; Kimura R; Tan TZ; Yamaguchi R; Ebi H Clin Cancer Res; 2020 Nov; 26(22):5962-5973. PubMed ID: 32900796 [TBL] [Abstract][Full Text] [Related]
17. KRAS inhibition activates an actionable CD24 'don't eat me' signal in pancreas cancer. Wei Y; Liu M; Yen EY; Yao J; Nguyen PT; Wang X; Yang Z; Yousef A; Pan D; Jin Y; Theady MS; Park J; Cai Y; Takeda M; Vasquez M; Zhou Y; Zhao H; Viale A; Wang H; Zhao D; DePinho RA; Yao W; Ying H bioRxiv; 2023 Sep; ():. PubMed ID: 37790498 [TBL] [Abstract][Full Text] [Related]